München (ots) - - Drei neue Folgen des erfolgreichen Dating-Formats - Singles wählen aus sechs nackten ...
Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
Huntington Beach, California and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics,
announced today that Palmetto GBA, California's Part B Medicare
administrator, has established coding guidelines for the company's
MammaPrint test. MammaPrint is Agendia's FDA-cleared breast cancer
recurrence test, which has been reimbursed by payors since 2008.
Patients across the United States can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed. The coding guidelines for healthcare providers are available at the Centers for Medicare and Medicaid Services (CMS) website at http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd_id=30376&lcd_ve rsion=5&show=all.
"Palmetto's decision to include MammaPrint in their reimbursement guidelines will provide greater access to this test for more women and their doctors when faced with difficult treatment decisions around breast cancer," said Dr. Richard Bender, Chief Medical Officer of Agendia.
MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure that patient safety and efficacy are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results, in addition to other clinical information and pathology tests, provide doctors with a clear rationale to evaluate the benefits of chemotherapy
All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.
Hans Herklots Valerie Delva
Head of Corporate Communications Account Executive
Agendia Ricochet Public Relations
+31-20-462-1557 Office +1-212-679-3300 x131 Office
+31-620-083-509 Mobile firstname.lastname@example.org
ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.ch
MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
email@example.com; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, firstname.lastname@example.org